null

Anti-Mouse CD279 (PD-1) - Fc Reduced (LALA-PG) Recombinant Monoclonal Antibody

SKU:
IVMB0280
Product Type:
Recombinant Monoclonal Antibody
Clone:
RMP1-14 (LALA-PG)
Protein:
PD-1
Isotype:
Mouse IgG2a k
Reactivity:
Mouse
Synonyms:
Programmed Death-1
CD279
PD1
PDCD1
Research Area:
Apoptosis
Cancer
Cell Biology
Cell Death
Immunology
Inhibitory Molecules
Tumor Suppressors
Endotoxin Level:
Low Endotoxin
Host Species:
Mouse-Rat Chimeric
Applications:
Blocking
FA
In Vivo
WB
$311 - $9,929
Frequently bought together:

Description

Anti-Mouse CD279 (PD-1) - Fc Reduced (LALA-PG) Recombinant Monoclonal Antibody

Introducing the Anti-Mouse CD279 (PD-1) Fc Reduced LALA-PG Recombinant Monoclonal Antibody from Assay Genie, an exceptional tool for researchers focusing on immune regulation and checkpoint pathways. This antibody targets Programmed Cell Death Protein 1 (PD-1), a critical checkpoint protein involved in the regulation of T-cell function and immune response. Engineered with a unique LALA-PG modification, this antibody ensures reduced Fc receptor binding, enhancing specificity and minimizing off-target effects. Ideal for applications in immunology research, PD-1 blockade studies, and cancer immunotherapy research, it offers unparalleled performance in various assays such as ELISA, flow cytometry, and functional assays. This product boasts high purity and low endotoxin levels, ensuring reliable and reproducible results.

It is available in a range of quantities to suit different experimental needs and is provided in a stable phosphate-buffered saline solution. Enhance your research capabilities with this versatile and high-quality antibody, designed to deliver precise and impactful results in studies related to immune checkpoints and therapeutic targets. PD-1, a crucial immune regulatory molecule, is predominantly expressed on T cells and plays a significant role in maintaining immune tolerance by inhibiting T-cell activation upon engagement with its ligands, PD-L1 or PD-L2. Understanding and targeting PD-1 pathways can lead to significant advancements in treatments for cancer, autoimmune diseases, and chronic infections.